TARSUS PHARMACEUTICALS, INC. Capital Expenditures Incurred but Not yet Paid
TARSUS PHARMACEUTICALS, INC. (TARS) reported Capital Expenditures Incurred but Not yet Paid of $623.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$288.00K, a 194.43% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $911.00K, a 2235.90% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $32.00K, a 21.95% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $1.16M, a 2000.00% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2025 was $1.53M, a 1446.46% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $99.00K, a 26.12% decline from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $134.00K, a 538.10% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $21.00K, a 950.00% increase from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$288.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $623.00K 10-Q · filed 2026-08-06 | $655.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $911.00K 10-Q · filed 2026-05-06 | $943.00K derived: sum of 2 quarters · filed 2026-05-06 | $2.10M derived: sum of 3 quarters · filed 2026-05-06 | $2.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.19M derived: sum of 2 quarters · filed 2026-02-23 | $1.49M derived: sum of 3 quarters · filed 2026-08-06 | $1.53M 10-K · filed 2026-02-23 |
| 2025-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.46M derived: sum of 2 quarters · filed 2026-08-06 | $1.50M 10-Q · filed 2025-11-04 | $1.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $305.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $344.00K 10-Q · filed 2026-08-06 | $385.00K derived: sum of 3 quarters · filed 2026-08-06 | $440.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $39.00K 10-Q · filed 2026-05-06 | $80.00K derived: sum of 2 quarters · filed 2026-05-06 | $135.00K derived: sum of 3 quarters · filed 2026-05-06 | $138.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $96.00K derived: sum of 2 quarters · filed 2026-02-23 | $99.00K derived: sum of 3 quarters · filed 2026-02-23 | $99.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $58.00K derived: sum of 2 quarters · filed 2025-11-04 | $58.00K 10-Q · filed 2025-11-04 | $160.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $3.00K 10-Q · filed 2025-08-06 | $105.00K derived: sum of 3 quarters · filed 2026-02-23 | $116.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | $102.00K derived: sum of 2 quarters · filed 2026-02-23 | $113.00K derived: sum of 3 quarters · filed 2026-02-23 | $134.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $113.00K derived: sum of 2 quarters · filed 2026-02-23 | $134.00K derived: sum of 3 quarters · filed 2026-02-23 | $134.00K 10-K · filed 2026-02-23 |
| 2023-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $32.00K derived: sum of 2 quarters · filed 2024-11-13 | $32.00K 10-Q · filed 2024-11-13 | $9.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $21.00K 10-Q · filed 2024-08-08 | -$2.00K derived: sum of 3 quarters · filed 2025-02-25 | -$17.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | -$23.00K derived: sum of 2 quarters · filed 2025-02-25 | -$38.00K derived: sum of 3 quarters · filed 2025-02-25 | -$20.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$38.00K derived: sum of 2 quarters · filed 2025-02-25 | -$20.00K derived: sum of 3 quarters · filed 2025-02-25 | $21.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.00K derived: sum of 2 quarters · filed 2023-11-09 | $44.00K 10-Q · filed 2023-11-09 | $46.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $59.00K 10-Q · filed 2023-08-10 | $61.00K derived: sum of 3 quarters · filed 2023-08-10 | $61.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $41.00K 10-Q · filed 2023-05-09 | $43.00K derived: sum of 2 quarters · filed 2023-05-09 | $43.00K derived: sum of 3 quarters · filed 2023-05-09 | $43.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $2.00K derived: sum of 2 quarters · filed 2023-03-17 | $2.00K derived: sum of 3 quarters · filed 2023-03-17 | $2.00K 10-K · filed 2023-03-17 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $34.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $34.00K derived: sum of 3 quarters · filed 2022-08-11 | -$13.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-11 | $34.00K derived: sum of 2 quarters · filed 2022-05-11 | -$13.00K derived: sum of 3 quarters · filed 2022-05-11 | $22.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$13.00K derived: sum of 2 quarters · filed 2022-03-14 | $22.00K derived: sum of 3 quarters · filed 2022-03-14 | $34.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | -$47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-25 | -$12.00K derived: sum of 2 quarters · filed 2021-08-05 | $0.00 10-Q · filed 2020-11-25 | -$13.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $47.00K 10-Q · filed 2021-08-05 | $34.00K derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $12.00K 10-Q · filed 2021-05-11 | -$1.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $10.00K 10-K · filed 2021-03-31 | ||
| 2019-09-30 | $23.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |